Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...

Vegetarian diets are linked with a lower risk of several cancers, including pancreatic, breast and prostate, according to a study that found no similar benefit — and even a higher chance of colon ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

The drug makes prostate cancer easier to detect and stage because it attaches to the cancer cells themselves. This marks the third PSMA‑targeted radiopharmaceutical manufactured at Huntsman Cancer ...

Chris Haynes: Los Angeles Clippers receiving multiple first round picks and Bennedict Mathurin form Indiana Pacers in exchange for Ivica Zubac, sources tell me.